Opthea Ltd (AU:OPT) — Market Cap & Net Worth
Market Cap & Net Worth: Opthea Ltd (OPT)
Opthea Ltd (AU:OPT) has a market capitalization of $9.68 Million (AU$13.68 Million) as of September 16, 2026. Listed on the AU stock exchange, this Australia-based company holds position #27257 globally and #1309 in its home market, demonstrating a -16.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Opthea Ltd's stock price AU$0.01 by its total outstanding shares 1367978173 (1.37 Billion). Also see Opthea Ltd asset portfolio for a full breakdown of the balance sheet.
Opthea Ltd Market Cap History: 2015 to 2026
Opthea Ltd's market capitalization history from 2015 to 2026. Data shows change from $336.16 Million to $9.68 Million (-24.74% CAGR). Also see OPT cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Opthea Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Australia All Ordinaries
AORD
|
$1.97 Trillion | 0.00% | #327 of 495 |
Weight: Opthea Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Opthea Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Opthea Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check OPT share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
23230.36x
Opthea Ltd's market cap is 23230.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $710.17 Million | $765.27K | -$6.51 Million | 928.00x | N/A |
| 2017 | $588.31 Million | $573.42K | -$6.19 Million | 1025.97x | N/A |
| 2018 | $487.45 Million | $1.14 Million | -$16.90 Million | 426.16x | N/A |
| 2019 | $2.50 Billion | $112.50K | -$20.91 Million | 22262.16x | N/A |
| 2020 | $1.61 Billion | $145.90K | -$16.12 Million | 11059.31x | N/A |
| 2021 | $1.09 Billion | $91.98K | -$60.79 Million | 11832.25x | N/A |
| 2022 | $768.92 Million | $125.05K | -$127.99 Million | 6149.09x | N/A |
| 2023 | $508.16 Million | $161.16K | -$211.88 Million | 3153.11x | N/A |
| 2024 | $784.02 Million | $124.67K | -$220.24 Million | 6289.00x | N/A |
| 2025 | $580.76 Million | $25.00K | -$162.79 Million | 23230.36x | N/A |
Competitor Companies of OPT by Market Capitalization
Companies near Opthea Ltd in the global market cap rankings as of September 16, 2026. Review OPT intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Opthea Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $519.51 |
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
Opthea Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Opthea Ltd's market cap moved from $336.16 Million to $ 9.68 Million, with a yearly change of -24.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$9.68 Million | -98.33% |
| 2025 | AU$580.76 Million | -25.93% |
| 2024 | AU$784.02 Million | +54.29% |
| 2023 | AU$508.16 Million | -33.91% |
| 2022 | AU$768.92 Million | -29.35% |
| 2021 | AU$1.09 Billion | -32.55% |
| 2020 | AU$1.61 Billion | -35.57% |
| 2019 | AU$2.50 Billion | +413.78% |
| 2018 | AU$487.45 Million | -17.14% |
| 2017 | AU$588.31 Million | -17.16% |
| 2016 | AU$710.17 Million | +111.26% |
| 2015 | AU$336.16 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Opthea Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.68 Million USD |
| MoneyControl | $9.68 Million USD |
| MarketWatch | $9.68 Million USD |
| marketcap.company | $9.68 Million USD |
| Reuters | $9.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Opthea Ltd
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more